PPIDT00374
Drug Information
| Name | Tisagenlecleucel |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB13881 |
| Type | biotech |
| Indication | Tisagenlecleucel is indicated for use in individuals aged 25 years and younger with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.[L41230] It is also used to treat adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.[L41230] Tisagenlecleucel is also indicated in adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.[L41230] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| — | Intravenous |
300600000 cells
|
| Injection, suspension | Intravenous |
2000001
|
| Injection, suspension | Intravenous |
300600.000 cells
|
| Injection, suspension | Intravenous |
60000001
|
| Suspension | Intravenous |
600000000 cells
|